newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China

Kinnate to retain Kinnjiu's cash, intellectual property and other assets, including key personnel and legal entity structureKinnate's cash runway still expected to fund current operations into mid-2024Trial sites open in